Recursion Pharmaceuticals, Inc. announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety, tolerability and pharmacokinetic profile of REC-3964. REC-3964 has been well tolerated with no serious adverse events (SAEs) reported.

REC-3964 is a novel non-antibiotic small molecule inhibitor of C. difficile toxins that is being developed for the potential treatment of Clostridioides difficile (C. diff) infection, a bacterial disease that impacts more than 730,000 people in the US and EU5 every year. REC-3964 is Recursion's first and most advanced new chemical entity, demonstrating the power of Recursion's platform to rapidly identify, validate, optimize and translate novel insights into clinical candidates. REC-3964 represents a novel small molecule approach designed to selectively inhibit the toxin produced by Clostridioides difficile in the gastrointestinal tract.

This molecule has the potential, when used as part of a treatment regimen, to prevent recurrent disease and/or other forms of C. diff infection, which is a leading cause of antibiotic-induced diarrhea sometimes leading to significant morbidity and mortality. More than 29,000 patients die in the US every year from C. diff infection.